Tag Archives: BLUE

Top 5 Clean Energy Stocks To Own For 2019

Uranium has been back in the news lately, not only due to its relationship with geopolitical maneuvering concerning nuclear weapons, but also as a necessary commodity in the global quest for clean, renewable energy.

The United States is the world’s largest producer of nuclear power, accounting for more than 30% of worldwide nuclear generation of electricity. While there has been little growth in new reactors being built in the last quarter century, the increasing demand for clean energy worldwide is sparking a demand for uranium to be enriched as nuclear fuel. Companies that mine and produce uranium, like Azincourt Uranium, Inc. (OTC: AZURF), are seeing the commodity investment market take a renewed interest in them, with uranium spot prices trending upward in the first quarter of 2017.

Top 5 Clean Energy Stocks To Own For 2019: Elbit Systems Ltd.(ESLT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Shares of Elbit Systems Ltd (NASDAQ:ESLT) have been given an average rating of “Hold” by the five research firms that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Booz Allen Hamilton Holding Corporation (NYSE: BAH) is estimated to report quarterly earnings at $0.46 per share on revenue of $1.67 billion.
    Momo Inc. (NASDAQ: MOMO) is projected to report quarterly earnings at $0.5 per share on revenue of $396.17 million.
    Multi-Color Corporation (NASDAQ: LABL) is expected to report quarterly earnings at $1.06 per share on revenue of $424.96 million.
    American Woodmark Corporation (NASDAQ: AMWD) is estimated to report quarterly earnings at $1.15 per share on revenue of $382.4 million.
    The Bank of Nova Scotia (NYSE: BNS) is projected to report quarterly earnings at $1.32 per share on revenue of $5.46 billion.
    Jianpu Technology Inc. (NYSE: JT) is expected to report quarterly loss at $0.04 per share on revenue of $47.51 million.
    Trans World Entertainment Corporation (NASDAQ: TWMC) is estimated to report earnings for its first quarter.
    Advanced Drainage Systems, Inc. (NYSE: WMS) is estimated to report quarterly loss at $0.06 per share on revenue of $249.44 million.
    Quotient Limited (NASDAQ: QTNT) is expected to report quarterly loss at $0.48 per share on revenue of $5.73 million.
    Elbit Systems Ltd. (NASDAQ: ESLT) is projected to report earnings for its first quarter.
    Evogene Ltd. (NASDAQ: EVGN) is expected to report earnings for its first quarter.

     

  • [By Lisa Levin] Gainers
    TherapeuticsMD, Inc. (NASDAQ: TXMD) rose 7.3 percent to $6.90 in pre-market trading after the company reported the FDA approval of TX-004HR: IMVEXXY (estradiol vaginal inserts) for moderate to severe dyspareunia due to menopause.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) rose 6.1 percent to $10.50 in pre-market trading after falling 1.20 percent on Tuesday
    Movado Group, Inc. (NYSE: MOV) shares rose 5.7 percent to $44.60 in pre-market trading after the company reported better-than-expected Q1 results and raised its guidance.
    salesforce.com, inc. (NYSE: CRM) rose 5.4 percent to $133.67 in pre-market trading after the company reported better-than-expected earnings for its first quarter and raised its forecast for the full year.
    Sirius XM Holdings Inc. (NASDAQ: SIRI) rose 5.3 percent to $7.35 in pre-market trading.
    PagSeguro Digital Ltd. (NYSE: PAGS) rose 5.3 percent to $33.50 in pre-market trading after reporting Q1 results.
    SpartanNash Co (NASDAQ: SPTN) rose 4.9 percent to $19.80 in pre-market trading after the company reported upbeat earnings for its first quarter on Tuesday.
    Groupon, Inc. (NASDAQ: GRPN) rose 4.9 percent to $4.95 in pre-market trading. Dalian Wanda will set up a joint venture with Tencent and Groupon's former local unit, Reuters reported.
    Okta, Inc. (NASDAQ: OKTA) rose 4.4 percent to $56 in pre-market trading after gaining 3.43 percent on Tuesday
    Elbit Systems Ltd. (NASDAQ: ESLT) rose 4.3 percent to $120.92 in pre-market trading after gaining 2.05 percent on Tuesday.
    STMicroelectronics N.V. (NYSE: STM) shares rose 3.7 percent to $23.78 in pre-market trading after falling 4.70 percent on Tuesday.
    EVINE Live Inc (NASDAQ: EVLV) shares rose 2.7 percent to $1.14 in pre-market trading after reporting Q1 results.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Stephan Byrd]

    BidaskClub upgraded shares of Elbit Systems (NASDAQ:ESLT) from a sell rating to a hold rating in a report issued on Wednesday.

    Several other equities research analysts have also weighed in on the company. ValuEngine upgraded Elbit Systems from a hold rating to a buy rating in a report on Thursday, March 1st. TheStreet lowered Elbit Systems from a b rating to a c+ rating in a report on Tuesday, May 29th. Finally, Chardan Capital restated a neutral rating on shares of Elbit Systems in a report on Friday, June 1st. Five investment analysts have rated the stock with a hold rating, Elbit Systems presently has an average rating of Hold and an average price target of $176.00.

  • [By Motley Fool Transcribers]

    Elbit Systems Ltd (NASDAQ:ESLT)Q2 2018 Earnings Conference CallAug. 16, 2018, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 Clean Energy Stocks To Own For 2019: bluebird bio, Inc.(BLUE)

Advisors’ Opinion:

  • [By Cory Renauer]

    CTX001 needs to show signs that boosting fetal hemoglobin can reduce dependence on blood transfusions better than another drug that’s much further ahead. One of CRISPR’s potential rivals, bluebird bio (NASDAQ:BLUE), has years of fairly successful data for LentiGlobin, a cellular therapy that simply inserts a functional copy of the faulty gene these patients inherited into their own stem cells.

  • [By Ethan Ryder]

    Blue Protocol (CURRENCY:BLUE) traded 5.2% lower against the US dollar during the one day period ending at 18:00 PM ET on June 27th. In the last seven days, Blue Protocol has traded down 29.4% against the US dollar. Blue Protocol has a total market capitalization of $3.16 million and approximately $3,034.00 worth of Blue Protocol was traded on exchanges in the last 24 hours. One Blue Protocol token can currently be bought for approximately $0.0862 or 0.00001406 BTC on exchanges including IDEX, YoBit, CoinExchange and EtherDelta (ForkDelta).

  • [By Todd Campbell]

    Additionally, liso-cel, the chimeric antigen receptor T-cell gene therapy Celgene acquired when it bought Juno earlier this year, and bb2121, a CAR-T under development with bluebird bio (NASDAQ:BLUE) for multiple myeloma, continue to progress toward regulators. 

  • [By Todd Campbell]

    Celgene is working with bluebird bio (NASDAQ:BLUE) on bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy for use in multiple myeloma. Initially, bb2121 is being studied in the fourth-line or higher setting, where there’s a significant need for new treatment. However, data observed so far suggests that it may eventually wind up being a successor to Revlimid and Pomalyst. 

Top 5 Clean Energy Stocks To Own For 2019: Rocky Mountain Chocolate Factory Inc.(RMCF)

Advisors’ Opinion:

  • [By Max Byerly]

    Rocky Mountain Chocolate Factory (NASDAQ: RMCF) and Tootsie Roll Industries (NYSE:TR) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

  • [By Ethan Ryder]

    Rocky Mountain Chocolate Factory (NASDAQ: RMCF) and Tootsie Roll Industries (NYSE:TR) are both small-cap retail/wholesale companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Top 5 Clean Energy Stocks To Own For 2019: Columbia Sportswear Company(COLM)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Schwab Charles Investment Management Inc. trimmed its position in Columbia Sportswear (NASDAQ:COLM) by 15.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 218,646 shares of the textile maker’s stock after selling 38,455 shares during the period. Schwab Charles Investment Management Inc. owned about 0.31% of Columbia Sportswear worth $20,000,000 as of its most recent SEC filing.

  • [By Shane Hupp]

    Brasada Capital Management LP grew its stake in shares of Columbia Sportswear (NASDAQ:COLM) by 25.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,669 shares of the textile maker’s stock after purchasing an additional 1,148 shares during the quarter. Brasada Capital Management LP’s holdings in Columbia Sportswear were worth $433,000 as of its most recent SEC filing.

  • [By Shane Hupp]

    Columbia Sportswear (NASDAQ:COLM) hit a new 52-week high and low during mid-day trading on Tuesday . The stock traded as low as $88.86 and last traded at $88.27, with a volume of 4020 shares traded. The stock had previously closed at $87.29.

  • [By Shane Hupp]

    Columbia Sportswear (NASDAQ:COLM) had its target price raised by research analysts at Wedbush from $102.00 to $103.00 in a research report issued on Wednesday. The firm presently has an “outperform” rating on the textile maker’s stock. Wedbush’s price target would indicate a potential upside of 13.99% from the company’s current price.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Columbia Sportswear (COLM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Clean Energy Stocks To Own For 2019: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    After looking at last week’s top-performing penny stocks, we’ll show you another penny stock that could jump over 230%…

    Penny Stock Current Share Price Last Week’s Gain
    vTv Therapeutics Inc. (NASDAQ: VTVT) $3.05 335.06%
    MagneGas Corp. (NASDAQ: MNGA) $0.30 116.67%
    Dragon Victory International Ltd. (NASDAQ: LYL) $2.33 93.80%
    Inpixon Inc. (NASDAQ: INPX) $0.30 85.59%
    Altimmune Inc. (NASDAQ: ALT) $4.91 64.55%
    Comstock Mining Inc. (NYSE: LODE) $0.21 52.07%
    Trevena Inc. (NASDAQ: TRVN) $2.94 46.70%
    Alliance MMA Inc. (NASDAQ: AMMA $0.31 41.09%
    Akers Biosciences Inc. (NASDAQ: AKER) $0.35 40.75%
    Level Brands Inc. (NYSE: LEVB) $4.88 40.22%

    First-time investors can find it incredibly difficult to identify penny stocks with real growth potential.

  • [By Money Morning Staff Reports]

    Here are last week’s top-performing penny stocks:

    Penny Stock Sector Current Share Price Last Week’s Gain
    OncoCyte Corp. (NYSE: OCX) Healthcare $4.98 159.38%
    Fortress Biotech (NASDAQ: FBIO) Healthcare $2.47 133.02%
    Trevena Inc. (NASDAQ: TRVN) Healthcare $1.01 86.69%
    Celldex Therapeutics Inc. (NASDAQ: CLDX) Healthcare $0.58 66.82%
    Wheeler Real Estate Investment Trust Inc.(NASDAQ: WHLR) Financial $1.80 63.64%
    Scynexis Inc. (NASDAQ: SCYX) Healthcare $1.13 53.64%
    Eldorado Gold Corp. (NYSE: EGO) Basic Materials $3.98 47.96%
    Novus Therapeutics Inc. (NASDAQ: NVUS) Healthcare $4.15 43.60%
    PHI Inc. (NASDAQ: PHII) Services $4.50 42.14%
    BioTime Inc. (NYSE: BTX) Healthcare $1.33 41.50%

    See Now: Our founder just released his No. 1 pick for 2019. Don’t miss this. See urgent briefing here…

  • [By Shane Hupp]

    Shares of Trevena Inc (NASDAQ:TRVN) have been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $5.54.

  • [By Stephan Byrd]

    ILLEGAL ACTIVITY WARNING: “Insider Buying: Trevena Inc (TRVN) CEO Purchases 50,000 Shares of Stock” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/4136441/insider-buying-trevena-inc-trvn-ceo-purchases-50000-shares-of-stock.html.

Best Blue Chip Stocks To Invest In Right Now

Shutterstock

Fact: When interest rates rise, you need to be in dividend-growth stocks.

Proof: They’ve handily beaten the S&P 500 in the 17 months since the Federal Reserve put the zero-interest-rate era on ice.

In just a moment, I’ll show you 2 terrific off-the-radar dividend-growth plays to snap up now—and 2 surprising blue chips you’ll want to keep well away from your nest egg.

First, take a look at how the iShares Core Dividend-Growth ETF (DGRO) has performed vs. the SPDR S&P 500 ETF (SPY) on a total-return basis since December 16, 2015, the day Janet Yellen raised rates for the first time in nine years.

The Dividend-Growth Edge in 1 Chart

Best Blue Chip Stocks To Invest In Right Now: United States Steel Corporation(X)

Advisors’ Opinion:

  • [By Lee Jackson]

    This venerable steel producer remains a favorite on Wall Street.United States Steel Corp. (NYSE: X) produces and sells flat-rolled and tubular steel products in North America and Europe. It operates through three segments.Its Flat-Rolled Products segment offers slabs, rounds, strip mill plates, sheets and tin mill products. This segment serves customers in the automotive, consumer and the combined industrial, service center and mining commercial markets.

  • [By Peter Graham]

    One seemingly interesting bright spot though now that the sector has come off a bit is steel. Two steel stocks in United States Steel Corporation (X) and Steel Dynamics, Inc. (STLD) not only are looking technically attractive once again, they’re offering some nice value on a fundamental basis, albeit for very different reasons.

  • [By Logan Wallace]

    TMX Group Ltd (TSE:X) – Equities researchers at National Bank Financial lowered their Q3 2018 earnings per share estimates for shares of TMX Group in a research report issued on Monday, July 16th. National Bank Financial analyst J. Gloyn now forecasts that the company will post earnings of $1.30 per share for the quarter, down from their prior estimate of $1.33. National Bank Financial currently has a “Outperform” rating and a $88.00 price target on the stock. National Bank Financial also issued estimates for TMX Group’s Q4 2018 earnings at $1.35 EPS and FY2019 earnings at $5.68 EPS.

Best Blue Chip Stocks To Invest In Right Now: Franco-Nevada Corporation(FNV)

Advisors’ Opinion:

  • [By Reuben Gregg Brewer]

    This, however, is where streaming company Wheaton Precious Metals (NYSE:WPM)and its peers Royal Gold (NASDAQ:RGLD) and Franco-Nevada (NYSE:FNV)come into play. Streaming companies provide cash up front to miners for the right to buy gold and silver in the future at reduced rates. Often miners use the money to build new mines. Wheaton provided $625 million in cash to Barrick for the development of Pascua-Lama. That is just one of 10 development projects in which Wheaton has invested. Its portfolio also contains 17 operating mines.

  • [By Ethan Ryder]

    Franco Nevada Corp (NYSE:FNV) (TSE:FNV) has received an average recommendation of “Hold” from the twelve research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $95.17.

  • [By Dan Caplinger]

    Franco-Nevada (NYSE:FNV) has done a good job recently of expanding its reach. After focusing almost exclusively on streaming agreements with mining partners in gold and other precious and base metals, the company decided recently to boost its exposure to oil and gas considerably. That’s proven to be an important move, as weaker gold production has been offset by better performance in its growing energy portfolio.

Best Blue Chip Stocks To Invest In Right Now: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Todd Campbell]

    It’s been a tough year for Celgene Corp. (NASDAQ:CELG)investors, but upcoming phase 3 dataon luspaterceptfromAcceleron Pharma (NASDAQ:XLRN)could rekindle interest in Celgene’s stock price. Acceleron is expected to report trial results for luspatercept in myelodysplastic syndromes (MDS) and beta thalassemia anytime now, and if the results are positive, Celgene thinks luspatercept could be a multibillion-dollar-per-year blockbuster.

  • [By Todd Campbell]

    In collaboration with Celgene Corp. (NASDAQ:CELG), Acceleron Pharma is developing luspatercept, an erythroid maturation agent (EMA) that addresses chronic anemia in MDS and beta-thalassemia by promoting the production of healthy red blood cells.

  • [By George Budwell]

    Shares of blue-chip biotech Celgene Corporation (NASDAQ:CELG) fell by a staggering 23.9% through the first six months of this year,according to data fromS&P Global Market Intelligence. The biotech’s former high-flying ways were halted this year by a slew of headwinds that all center around the upcoming patent expiration for the top-selling multiple myeloma drug Revlimid.

  • [By George Budwell]

    Top healthcare stocks CVS Health Corporation (NYSE:CVS) and Celgene Corporation (NASDAQ:CELG), for example, come across as downright bargains for a variety of reasons right now. Read on the find out more.

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) has been the hands-down winner over Celgene (NASDAQ:CELG) in terms of stock performance over the last year. It’s the same story for revenue generated. Celgene beat Amgen in earnings, but only because of a technicality: Amgen incurred a big one-time tax hit in 2017.

  • [By Paul Ausick]

    Lingering outside the spotlight of the top 10 most shorted Nasdaq stocks again in the most recent period were Celgene Corp. (NASDAQ: CELG), Cisco Systems Inc. (NASDAQ: CSCO) and Twenty-First Century Fox Inc. (NASDAQ: FOXA).

Best Blue Chip Stocks To Invest In Right Now: bluebird bio, Inc.(BLUE)

Advisors’ Opinion:

  • [By Keith Speights]

    Bellicum Pharmaceuticals (NASDAQ:BLCM) and bluebird bio (NASDAQ:BLUE) are both clinical-stage biotechs that are developing cutting-edge therapies to treat cancer and other diseases. But the fortunes of these two biotechs have been very different over the last 12 months. Bellicum stock is down 37% during the period, while Bluebird’s share price has soared more than 125%.

  • [By Ethan Ryder]

    Blue Protocol (CURRENCY:BLUE) traded 5.2% lower against the US dollar during the one day period ending at 18:00 PM ET on June 27th. In the last seven days, Blue Protocol has traded down 29.4% against the US dollar. Blue Protocol has a total market capitalization of $3.16 million and approximately $3,034.00 worth of Blue Protocol was traded on exchanges in the last 24 hours. One Blue Protocol token can currently be bought for approximately $0.0862 or 0.00001406 BTC on exchanges including IDEX, YoBit, CoinExchange and EtherDelta (ForkDelta).

  • [By Todd Campbell]

    Celgene is working with bluebird bio (NASDAQ:BLUE) on bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy for use in multiple myeloma. Initially, bb2121 is being studied in the fourth-line or higher setting, where there’s a significant need for new treatment. However, data observed so far suggests that it may eventually wind up being a successor to Revlimid and Pomalyst.

  • [By Stephan Byrd]

    bluebird bio (NASDAQ:BLUE)‘s stock had its “underweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report issued on Wednesday.

Best Blue Chip Stocks To Invest In Right Now: Apple Inc.(AAPL)

Advisors’ Opinion:

  • [By Ashraf Eassa]

    It’s widely rumored that Apple(NASDAQ:AAPL) intends to launch three new iPhone models this year. At the bottom of the product stack is supposed to be a device with a liquid crystal display (LCD) that measures 6.1 inches along the diagonal.

  • [By Evan Niu, CFA]

    This all comes as Apple(NASDAQ:AAPL) is preparing to take Apple News to the next level in iOS 12, incorporating the service across other apps and services while redesigning the interface and bringing it to the Mac. Apple is taking news curation and distribution very seriously, presumably ahead of its rumored launch of a premium news subscription.

  • [By Paul Ausick]

    Qualcomm reaffirmed its “high confidence” that the merger will result in adjusted EPS in fiscal year 2019 of $6.75 to $7.50, excluding royalties and other revenues from Apple Inc. (NASDAQ: AAPL) and other licensees currently disputing payments to Qualcomm. The adjusted EPS figure includes a $1 billion cost reduction program and a boost of $1.50 in EPS from NXP.

  • [By Evan Niu, CFA]

    In addition to growing its services business, we know that Apple (NASDAQ:AAPL) is working on a new suite of audio accessories, including premium over-ear headphones that would compete with market leaders like Bose. The Mac maker has also been widely reported to be working on second-generation AirPods, which have proven to be a sleeper hit; the next version will likely include water resistance as a headline selling feature.

  • [By Douglas A. McIntyre]

    Apple Inc. (NASDAQ: AAPL) is the most valuable company in America based on market cap and is unlikely to let go of that position in the foreseeable future. However, the race for second place has tightened as Microsoft Corp. (NASDAQ: MSFT) has caught up with Amazon.com Inc. (NASDAQ: AMZN).

Best Blue Chip Stocks To Invest In Right Now: Schwab US Large-Cap ETF (SCHX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Milestone Group Inc. decreased its stake in Schwab US Large-Cap ETF (NYSEARCA:SCHX) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 63,425 shares of the company’s stock after selling 2,710 shares during the period. Schwab US Large-Cap ETF makes up 0.7% of Milestone Group Inc.’s investment portfolio, making the stock its 19th largest holding. Milestone Group Inc.’s holdings in Schwab US Large-Cap ETF were worth $4,001,000 as of its most recent filing with the Securities & Exchange Commission.

Top 10 Bank Stocks To Invest In 2019

Toys “R” Us is on its way out, but KB Toys is set to pop back up.

Strategic Marks, a company that buys and revitalizes defunct brands, owns the KB name and plans to open 1,000 pop-up KB Toys stores for Black Friday and the holiday shopping season.

“My assumption is that there’s about half a billion dollars worth of toys that have been produced for Toys “R” Us with no place to go,” said Strategic Marks president Ellia Kassoff, in a phone interview with CNNMoney. “That’s a big, big void that we’re hoping to fill up.”

Toys “R” Us, which filed for bankruptcy last year, announced last week that it expects to close all of its 735 stores in the US. Those closures will put 31,000 people out of work and hurt toy manufacturers that depended on the national retailer for distribution.

Kassoff said he’s been in contact with Hasbro Inc. (HAS) and Mattel, Inc. (MAT) and up to 200 smaller toy suppliers who are looking for new brick and mortar retailers. He said he plans to take advantage of a glut of toy manufacturers that have inventory but no place to sell it.

Top 10 Bank Stocks To Invest In 2019: Insmed, Inc.(INSM)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Insmed Inc. (NASDAQ: INSM) was raised to Outperform from Neutral at Credit Suisse.

    Lululemon Athletica Inc. (NASDAQ: LULU) was downgraded to Hold from Buy at Needham, based on the run-up in shares and on a harder earnings comparison that will be harder to beat. Lululemon was up 1% at $96.31 but was down 2% at $94.30 on Monday. It had a consensus target price of $89.93.

  • [By Lisa Levin] Gainers
    Check-Cap Ltd. (NASDAQ: CHEK) shares rose 78.82 percent to close at $7.26 on Monday.
    GEE Group, Inc. (NYSE: JOB) shares jumped 18 percent to close at $2.36.
    McDermott International, Inc. (NYSE: MDR) climbed 15.7 percent to close at $7.00 after the UK-based offshore oil service company Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron Company.
    Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) gained 17.21 percent to close at $3.61.
    Stars Group Inc. (NASDAQ: TSG) rose 14.16 percent to close at $33.45. Stars Group Inc (NASDAQ: TSG) announced plans to acquire Sky Betting & Gaming for $4.7 billion.
    China Internet Nationwide Financial Services Inc. (NASDAQ: CIFS) shares jumped 12.79 percent to close at $25.58.
    Nautilus, Inc. (NYSE: NLS) shares gained 11.52 percent to close at $15.00. Nautilus is expected to release Q1 results on May 7, 2018. Craig-Hallum initiated coverage on Nautilus with a Buy rating and a $19.00 price target.
    Box, Inc. (NYSE: BOX) rose 10.94 percent to close at $22.91.
    Insmed Incorporated (NASDAQ: INSM) shares rose 10.76 percent to close at $26.05. Credit Suisse upgraded Insmed from Neutral to Outperform.
    NextDecade Corporation (NASDAQ: NEXT) shares rose 10.02 percent to close at $6.48.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) shares gained 8.37 percent to close at $2.46 on Monday after falling 10.98 percent on Friday.
    Cambium Learning Group, Inc. (NASDAQ: ABCD) shares gained 7.81 percent to close at $11.11.
    Vectren Corporation (NYSE: VVC) shares rose 7.26 percent to close at $70.31. CenterPoint Energy, Inc. (NYSE: CNP) announced plans to acquire Vectren for $72 per share in cash.
    Tennant Company (NYSE: TNC) rose 6.66 percent to close at $74.45 after the company posted upbeat Q1 results and raised its FY18 earnings outlook.
    Hanesbrands Inc.
  • [By Lisa Levin] Gainers
    Valeritas Holdings, Inc. (NASDAQ: VLRX) shares jumped 17 percent to $3.65.
    Cambium Learning Group, Inc. (NASDAQ: ABCD) shares rose 13.5 percent to $11.70.
    McDermott International, Inc. (NYSE: MDR) gained 11.6 percent to $6.75 after the UK-based offshore oil service company Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron Company.
    Nautilus, Inc. (NYSE: NLS) shares jumped 11.2 percent to $14.95. Nautilus is expected to release Q1 results on May 7, 2018. Craig-Hallum initiated coverage on Nautilus with a Buy rating and a $19.00 price target.
    GEE Group, Inc. (NYSE: JOB) shares gained 11 percent to $2.2199.
    Check-Cap Ltd. (NASDAQ: CHEK) surged 10.8 percent to $4.50.
    Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) rose 10.1 percent to $3.39.
    Stars Group Inc. (NASDAQ: TSG) climbed 9.6 percent to $32.10. Stars Group Inc (NASDAQ: TSG) announced plans to acquire Sky Betting & Gaming for $4.7 billion.
    Insmed Incorporated (NASDAQ: INSM) shares jumped 9.1 percent to $25.66. Credit Suisse upgraded Insmed from Neutral to Outperform.
    Tennant Company (NYSE: TNC) rose 8.4 percent to $75.65 after the company posted upbeat Q1 results and raised its FY18 earnings outlook.
    Command Security Corporation (NYSE: MOC) shares gained 6.4 percent to $3.0960 after the company disclosed a $23 million five-year contract with LaGuardia Gateway Partners for LaGuardia Airport New Central Terminal Building.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) rose 6.2 percent to $2.41 after falling 10.98 percent on Friday.
    Vectren Corporation (NYSE: VVC) shares rose 5.7 percent to $69.31. CenterPoint Energy, Inc. (NYSE: CNP) announced plans to acquire Vectren for $72 per share in cash.
    Hanesbrands Inc. (NYSE: HBI) gained 4.9 percent to $18.035. Stifel Nicolaus upgraded Hanesbrands from Hold to Buy.
    M

Top 10 Bank Stocks To Invest In 2019: Zosano Pharma Corporation(ZSAN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Zosano Pharma Corp. (NASDAQ: ZSAN) dropped about 17% Tuesday to post a new 52-week low of $0.54 after closing at $0.65 on Friday. Volume was around 720,000, about 10% below the daily average of around 850,000. The company had no specific news.

  • [By Joseph Griffin]

    Zosano Pharma (NASDAQ:ZSAN) will announce its earnings results after the market closes on Tuesday, May 15th.

    Zosano Pharma (NASDAQ:ZSAN) last issued its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($3.80) EPS for the quarter, topping analysts’ consensus estimates of ($4.80) by $1.00.

Top 10 Bank Stocks To Invest In 2019: bluebird bio, Inc.(BLUE)

Advisors’ Opinion:

  • [By Todd Campbell, Leo Sun, and Daniel Miller]

    For instance, the company recently acquired Juno Therapeutics to get its hands on a pipeline of chimeric antigen receptor T-cell gene therapies (CAR-Ts). CAR-Ts represent one of the biggest recent advances in treating blood cancer, and depending on trial results, the first CAR-T from this collaboration could be filed for approval next year. Similarly, Celgene is partnering with bluebird bio (NASDAQ:BLUE) on bb2121, a CAR-T for multiple myeloma. So far, bb2121 is delivering 90%-plus response rates in heavily pre-treated patients, and if that success continues, it could end up on regulators’ desk for approval next year, too.

  • [By Rafi Farber]

    Heres some perspective. Within the past decade, University of Pennsylvania has allied with Novartis A.G. (NYSE: NVS), Baylor College of Medicine with Bluebird Bio Inc. (NASDAQ: BLUE) and Celgene Corp. (NASDAQ:CELG), Memorial Sloan Kettering Cancer Center and the Fred Hutchinson Cancer Research Center with Juno Therapeutics Inc. (NASDAQ: JUNO) (which Celgene just got clearance to acquire), and the National Cancer Institute with Kite Pharma, which was acquired last year byGilead Sciences Inc. (NASDAQ: GILD).

  • [By Ethan Ryder]

    Blue Protocol (CURRENCY:BLUE) traded down 9.1% against the U.S. dollar during the 24-hour period ending at 11:00 AM Eastern on May 12th. One Blue Protocol token can now be purchased for about $0.18 or 0.00002166 BTC on cryptocurrency exchanges including CoinExchange, EtherDelta (ForkDelta), IDEX and YoBit. In the last seven days, Blue Protocol has traded down 16.3% against the U.S. dollar. Blue Protocol has a market capitalization of $6.65 million and $31,443.00 worth of Blue Protocol was traded on exchanges in the last 24 hours.

Top 10 Bank Stocks To Invest In 2019: Diageo plc(DEO)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Diageo (NYSE:DEO) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Monday.

Top 10 Bank Stocks To Invest In 2019: Invesco Advantage Municipal Income Trust II(VKI)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Wedbush Securities Inc. bought a new stake in Invesco Advantage Municipal Income Trust II (NYSEAMERICAN:VKI) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 35,963 shares of the financial services provider’s stock, valued at approximately $382,000. Wedbush Securities Inc. owned 0.08% of Invesco Advantage Municipal Income Trust II as of its most recent SEC filing.

Top 10 Bank Stocks To Invest In 2019: NVR Inc.(NVR)

Advisors’ Opinion:

  • [By JJ Kinahan]

    Next week is big for housing numbers. March existing home sales figures are scheduled for  Monday and new home sales for March along with the February S&P Case-Shiller Home Price Index on Tuesday. As for homebuilders, Pulte Group, Inc. (NYSE: PHM) is scheduled to report  Q1 results Tuesday, and D.R. Horton Inc (NYSE: DHI) is scheduled to report fiscal Q2 numbers on Thursday. The industry already has seen strong Q1 results from Lennar Corporation (NYSE: LEN), and housing starts and building permits in March rose more than expected. These results, as well as those and the economic data from next week could provide clues for the industry going forward. After NVR, Inc. (NYSE: NVR) reports results this morning, Meritage Homes Corp. (NYSE: MTH) releases its Q1 results April 25. We’ll have to wait until next month for some of the other homebuilders, as well as from home improvement companies Home Depot, Inc. (NYSE: HD) and Lowe’s Companies Inc (NYSE: LOW), before we get a more complete snapshot of the housing market.

  • [By Jason Hall]

    Priestley:Yeah,absolutely. The first stock that you mentioned was NVR (NYSE:NVR). They focus on building luxury homes in Delaware, Maryland, North Carolina, Pennsylvania,and Virginia. They have three distinct brands:Ryan Homes, NV Homes and Heartland Homes. They’reactually the most expensive, I think, of the stocks that we’re going to talk about today. Their P/E is at 24X. But they’re also the biggest, and the past 12 months have seen the stock come up almost 50%. So, great pick! What exactly attracted you to NVR?

  • [By Stephan Byrd]

    NVR, Inc. (NYSE:NVR) Director Susan Williamson Ross purchased 70 shares of the company’s stock in a transaction on Tuesday, May 15th. The stock was purchased at an average price of $2,995.20 per share, for a total transaction of $209,664.00. Following the purchase, the director now directly owns 64,191 shares of the company’s stock, valued at approximately $192,264,883.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

  • [By Tyler Crowe]

    For a business that is supposed to be relatively seasonal and cyclical, NVR (NYSE:NVR) has been enjoying an impressive run of growth. Not only did the company deliver impressive top- and bottom-line expansion, but it also showed positive trends on just about every operating metric. If there was one thing to critique, it’s how management is dividing up the benefits of these boom times.

Top 10 Bank Stocks To Invest In 2019: NCI Building Systems, Inc.(NCS)

Advisors’ Opinion:

  • [By Max Byerly]

    Several equities research analysts have issued reports on the stock. ValuEngine cut shares of NCI Building Systems from a “buy” rating to a “hold” rating in a research note on Thursday. Stephens reaffirmed a “hold” rating and set a $20.00 price target on shares of NCI Building Systems in a research note on Thursday, March 15th. Barclays reaffirmed an “overweight” rating on shares of NCI Building Systems in a research note on Thursday, March 8th. Royal Bank of Canada reaffirmed a “buy” rating and set a $20.00 price target on shares of NCI Building Systems in a research note on Thursday, March 8th. Finally, Zacks Investment Research cut shares of NCI Building Systems from a “buy” rating to a “hold” rating in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $20.00.

    COPYRIGHT VIOLATION WARNING: “NCI Building Systems (NCS) Receiving Favorable Press Coverage, Report Finds” was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3361896/nci-building-systems-ncs-receiving-favorable-press-coverage-report-finds.html.

    NCI Building Systems Company Profile

  • [By Stephan Byrd]

    NCI Building Systems (NYSE:NCS) was the target of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 800,076 shares, a growth of 50.7% from the April 13th total of 531,044 shares. Currently, 1.9% of the company’s shares are short sold. Based on an average daily trading volume, of 323,193 shares, the short-interest ratio is presently 2.5 days.

Top 10 Bank Stocks To Invest In 2019: Envestnet, Inc(ENV)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Financial services companies rely on the health of the markets to bring them business from the large institutions that are their best customers. With a bull market that’s almost a decade long at this point, Wall Street has never been stronger, and that’s given a big boost to financial information technology specialist Envestnet (NYSE:ENV). Yet as volatility returns to the stock market in early 2018, some investors feared that Envestnet’s time in the sun might soon end and give way to more difficult conditions looking ahead.

  • [By Stephan Byrd]

    Zillow (NASDAQ: ZG) and Envestnet (NYSE:ENV) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Top 10 Bank Stocks To Invest In 2019: Banner Corporation(BANR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Here are some of the news articles that may have impacted Accern’s rankings:

    Get Banner alerts:

    Banner Year for Asset Managers Could Be Catalyst for Change (markets.financialcontent.com) Zacks: Analysts Anticipate Banner Co. (BANR) to Announce $0.86 EPS (americanbankingnews.com) Banner Bank signs long lease for highly visible Sacramento site (finance.yahoo.com) Steven W. Rust Sells 511 Shares of Banner Co. (BANR) Stock (americanbankingnews.com) FY2018 Earnings Estimate for Banner Co. (BANR) Issued By DA Davidson (americanbankingnews.com)

    NASDAQ BANR opened at $57.47 on Friday. The company has a quick ratio of 0.90, a current ratio of 0.92 and a debt-to-equity ratio of 0.24. The firm has a market cap of $1,896.48, a P/E ratio of 19.22, a PEG ratio of 1.66 and a beta of 0.96. Banner has a 1 year low of $52.07 and a 1 year high of $62.75.

Top 10 Bank Stocks To Invest In 2019: Tenaris S.A.(TS)

Advisors’ Opinion:

  • [By Logan Wallace]

    ValuEngine upgraded shares of Tenaris (NYSE:TS) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning.

    Other research analysts have also issued research reports about the company. Piper Jaffray set a $40.00 target price on Tenaris and gave the stock a buy rating in a research report on Saturday, March 10th. Guggenheim restated a buy rating and set a $46.00 price objective on shares of Tenaris in a research report on Friday, March 2nd. Barclays restated a buy rating and set a $41.00 price objective on shares of Tenaris in a research report on Tuesday, February 27th. Loop Capital boosted their price objective on Tenaris from $39.00 to $43.00 and gave the company a buy rating in a research report on Thursday, March 22nd. Finally, Citigroup upgraded Tenaris from a neutral rating to a buy rating and set a $43.00 price objective for the company in a research report on Wednesday, April 11th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have given a buy rating to the stock. Tenaris currently has a consensus rating of Buy and a consensus price target of $39.08.

Top 5 Stocks To Watch For 2018

Many workers look forward to retirement and the more laid-back lifestyle it allows for. But if you retire before you’re actually ready, you could wind up majorly regretting that decision. With that in mind, here are a few signs that you’re not actually prepared to retire — even if you think you are.

1. You haven’t saved enough

Maybe you’re sitting on a nest egg with several hundred thousand dollars and are thinking you’re in good shape for retirement. But while, say, a $300,000 savings balance is nothing to scoff at, it most likely won’t buy you the retirement lifestyle you’re hoping for.

For years, financial experts have been suggesting a 4% annual withdrawal rate from savings during retirement. Withdrawing roughly 4% of your nest egg each year is, based on historical data, likely to make it last for 30 years. But if you apply a 4% withdrawal rate to a $300,000 savings balance, that only gives you $12,000 a year, which is hardly enough to live on.

Image source: Getty Images.

Top 5 Stocks To Watch For 2018: Avery Dennison Corporation(AVY)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Strategy Asset Managers LLC acquired a new stake in Avery Dennison (NYSE:AVY) during the first quarter, HoldingsChannel.com reports. The firm acquired 23,500 shares of the industrial products company’s stock, valued at approximately $2,497,000.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Thermo Fisher Scientific Inc. (NYSE: TMO) is projected to report quarterly earnings at $2.4 per share on revenue of $5.63 billion.
    Ford Motor Company (NYSE: F) is expected to report quarterly earnings at $0.41 per share on revenue of $37.16 billion.
    Twitter, Inc. (NYSE: TWTR) is projected to report quarterly earnings at $0.11 per share on revenue of $605.26 million.
    Comcast Corporation (NASDAQ: CMCSA) is expected to report quarterly earnings at $0.59 per share on revenue of $22.75 billion.
    General Dynamics Corporation (NYSE: GD) is estimated to report quarterly earnings at $2.52 per share on revenue of $7.6 billion.
    The Boeing Company (NYSE: BA) is expected to report quarterly earnings at $2.58 per share on revenue of $22.24 billion.
    Anthem, Inc. (NYSE: ANTM) is estimated to report quarterly earnings at $4.91 per share on revenue of $22.52 billion.
    Viacom, Inc. (NASDAQ: VIAB) is projected to report quarterly earnings at $0.79 per share on revenue of $3.04 billion.
    Northrop Grumman Corporation (NYSE: NOC) is estimated to report quarterly earnings at $3.61 per share on revenue of $6.61 billion.
    Rockwell Automation Inc. (NYSE: ROK) is expected to report quarterly earnings at $1.81 per share on revenue of $1.66 billion.
    Wipro Limited (NYSE: WIT) is projected to report quarterly earnings at $0.07 per share on revenue of $2.15 billion.
    The Goodyear Tire & Rubber Company (NASDAQ: GT) is expected to report quarterly earnings at $0.46 per share on revenue of $3.82 billion.
    Owens Corning (NYSE: OC) is projected to report quarterly earnings at $0.97 per share on revenue of $1.62 billion.
    T. Rowe Price Group, Inc. (NASDAQ: TROW) is estimated to report quarterly earnings at $1.71 per share on revenue of $1.29 billion.
    Dr Pepper Snapple Group, Inc. (NYSE: DPS) is expected to report quarterly earnings at $1.04 per share on revenue of $1.57 billion.
    Sirius XM Holdings Inc. (NASDAQ: SI
  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Avery Dennison (AVY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Stocks To Watch For 2018: Flexsteel Industries, Inc.(FLXS)

Advisors’ Opinion:

  • [By Shane Hupp]

    BidaskClub cut shares of Flexsteel Industries (NASDAQ:FLXS) from a hold rating to a sell rating in a research report released on Friday morning.

    Separately, ValuEngine lowered shares of Flexsteel Industries from a hold rating to a sell rating in a research report on Friday, April 27th.

Top 5 Stocks To Watch For 2018: FS Bancorp, Inc.(FSBW)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on FS Bancorp (FSBW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    FS Bancorp (NASDAQ:FSBW) – Research analysts at FIG Partners boosted their Q2 2018 earnings estimates for FS Bancorp in a research report issued to clients and investors on Thursday, May 3rd. FIG Partners analyst T. Coffey now anticipates that the bank will post earnings per share of $1.16 for the quarter, up from their prior forecast of $1.13. FIG Partners also issued estimates for FS Bancorp’s FY2018 earnings at $4.70 EPS, Q1 2019 earnings at $1.08 EPS, Q4 2019 earnings at $1.33 EPS and FY2019 earnings at $5.09 EPS.

Top 5 Stocks To Watch For 2018: bluebird bio, Inc.(BLUE)

Advisors’ Opinion:

  • [By Brian Orelli]

    bluebird bio (NASDAQ:BLUE) reportedfirst-quarter earnings last week, but like the biotech typically does, management didn’t hold a conference call, which makes the earnings release more of a rehash of the quarter than an actual update.

  • [By Ethan Ryder]

    Blue Protocol (CURRENCY:BLUE) traded down 9.1% against the U.S. dollar during the 24-hour period ending at 11:00 AM Eastern on May 12th. One Blue Protocol token can now be purchased for about $0.18 or 0.00002166 BTC on cryptocurrency exchanges including CoinExchange, EtherDelta (ForkDelta), IDEX and YoBit. In the last seven days, Blue Protocol has traded down 16.3% against the U.S. dollar. Blue Protocol has a market capitalization of $6.65 million and $31,443.00 worth of Blue Protocol was traded on exchanges in the last 24 hours.

  • [By Keith Speights]

    Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past, though. Which of these two clinical-stage biotech stocks is the better pick for investors now?

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Todd Campbell, Leo Sun, and Daniel Miller]

    For instance, the company recently acquired Juno Therapeutics to get its hands on a pipeline of chimeric antigen receptor T-cell gene therapies (CAR-Ts). CAR-Ts represent one of the biggest recent advances in treating blood cancer, and depending on trial results, the first CAR-T from this collaboration could be filed for approval next year. Similarly, Celgene is partnering with bluebird bio (NASDAQ:BLUE) on bb2121, a CAR-T for multiple myeloma. So far, bb2121 is delivering 90%-plus response rates in heavily pre-treated patients, and if that success continues, it could end up on regulators’ desk for approval next year, too.

Top 5 Stocks To Watch For 2018: SPDR S&P Bank ETF (KBE)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of KELLOGG W K FOUNDATION TRUST’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=KELLOGG+W+K+FOUNDATION+TRUST

    These are the top 5 holdings of KELLOGG W K FOUNDATION TRUSTKellogg Co (K) – 67,606,838 shares, 98.23% of the total portfolio. Shares reduced by 0.48%SPDR Select Sector Fund – Energy Select Sector (XLE) – 769,255 shares, 1.19% of the total portfolio. SPDR S&P Bank (KBE) – 534,408 shares, 0.54% of the total portfolio. Shares reduced by 37.08%MuleSoft Inc (MULE) – 73,513 shares, 0.04% of the total portfolio. New PositioniShares Russell 1000 Value (IWD) – 0 shares, 0% of the total portfol

Top Energy Stocks To Invest In 2019

The Canadian energy companies may be out of favor, but that has not stopped several of them from posting decent operating results. Investors can invest in Canadian companies far more cheaply than Permian operators. Yet, the results in Canada appear every bit as competitive. Obsidian Energy (OBE) just reported about C$.38 per share cash flow. That is very roughly one-fourth of the current selling price. Cash flow increased despite the WCS price weakness and all the headlines about the challenges facing Canadian producers.

Source: Obsidian Energy Fourth Quarter 2018 Earnings Press Release

Top Energy Stocks To Invest In 2019: bluebird bio, Inc.(BLUE)

Advisors’ Opinion:

  • [By Rafi Farber]

    Heres some perspective. Within the past decade, University of Pennsylvania has allied with Novartis A.G. (NYSE: NVS), Baylor College of Medicine with Bluebird Bio Inc. (NASDAQ: BLUE) and Celgene Corp. (NASDAQ:CELG), Memorial Sloan Kettering Cancer Center and the Fred Hutchinson Cancer Research Center with Juno Therapeutics Inc. (NASDAQ: JUNO) (which Celgene just got clearance to acquire), and the National Cancer Institute with Kite Pharma, which was acquired last year byGilead Sciences Inc. (NASDAQ: GILD).

  • [By Ethan Ryder]

    Blue Protocol (CURRENCY:BLUE) traded down 9.1% against the U.S. dollar during the 24-hour period ending at 11:00 AM Eastern on May 12th. One Blue Protocol token can now be purchased for about $0.18 or 0.00002166 BTC on cryptocurrency exchanges including CoinExchange, EtherDelta (ForkDelta), IDEX and YoBit. In the last seven days, Blue Protocol has traded down 16.3% against the U.S. dollar. Blue Protocol has a market capitalization of $6.65 million and $31,443.00 worth of Blue Protocol was traded on exchanges in the last 24 hours.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Todd Campbell, Leo Sun, and Daniel Miller]

    For instance, the company recently acquired Juno Therapeutics to get its hands on a pipeline of chimeric antigen receptor T-cell gene therapies (CAR-Ts). CAR-Ts represent one of the biggest recent advances in treating blood cancer, and depending on trial results, the first CAR-T from this collaboration could be filed for approval next year. Similarly, Celgene is partnering with bluebird bio (NASDAQ:BLUE) on bb2121, a CAR-T for multiple myeloma. So far, bb2121 is delivering 90%-plus response rates in heavily pre-treated patients, and if that success continues, it could end up on regulators’ desk for approval next year, too.

  • [By Keith Speights]

    Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past, though. Which of these two clinical-stage biotech stocks is the better pick for investors now?

  • [By Brian Orelli]

    bluebird bio (NASDAQ:BLUE) reportedfirst-quarter earnings last week, but like the biotech typically does, management didn’t hold a conference call, which makes the earnings release more of a rehash of the quarter than an actual update.

Top Energy Stocks To Invest In 2019: Wabash National Corporation(WNC)

Advisors’ Opinion:

  • [By Tyler Crowe]

    It wasn’t that long ago that concerns about a downturn in the truck trailer business had investors concerned that Wabash National’s (NYSE:WNC) best days were behind it. Those concerns seem to have been overblown, though, as demand for Wabash’s products were high enough for management to raise its sales guidance for the year.

Top Energy Stocks To Invest In 2019: Littelfuse Inc.(LFUS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Littelfuse (NASDAQ:LFUS) Director John E. Major sold 1,648 shares of the company’s stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $215.86, for a total value of $355,737.28. Following the completion of the transaction, the director now directly owns 26,254 shares in the company, valued at approximately $5,667,188.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

  • [By Ethan Ryder]

    Littelfuse (NASDAQ:LFUS) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday.

  • [By Stephan Byrd]

    Littelfuse (NASDAQ: LFUS) and ABB Group (NYSE:ABB) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.

Chimeric antigen receptor T-cell (CAR-T) therapies and gene therapies are hot commodities these days. But some small biotechs developing CAR-T drugs and gene therapies are hotter than others.

Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past, though. Which of these two clinical-stage biotech stocks is the better pick for investors now?

Cancer cell and DNA strand

Image source: Getty Images.

The case for Ziopharm

The best argument for buying Ziopharm stock right now is the biotech’s awkwardly named lead candidate,Ad-RTS-hIL-12. The gene-therapy product is anadenoviral vector — a genetically engineered adenovirus designed to insert a gene into a cell. Ad-RTS-hIL-12 is administered through an injection into a tumor to cause a controlled expression of IL-12, a cell-signaling molecule that helps the immune system attack tumors.

Ziopharm hoped to initiate a pivotal phase 3 clinical study in the second half of 2018 evaluating Ad-RTS-hIL-12 in combination with small-molecule activator ligandveledimexin treating recurrent glioblastoma multiforme (rGBM), an aggressive form of brain cancer. However, the company announced on Thursday that it put those plans on hold while it resolves some technical manufacturing issues.

The gene therapy is a promising one. Ad-RTS-hIL-12 produced positive results in earlier clinical studies. In particular, Ziopharm reported that its lead candidate turned cold tumors hot. With hot tumors, the immune system remains engaged in attacking cancer cells even after a tumor is removed. That’s not the case with cold tumors.

The biotech is also evaluating Ad-RTS-hIL-12 in phase 1 clinical studies targeting treatment of brain cancer. One of those studies combines Bristol-Myers Squibb’s checkpoint inhibitor Opdivo with Ziopharma’s gene therapy in treating rGBM. Another includes Ad-RTS-hIL-12 in combination with veledimexin treating brain tumors in pediatric patients.

Ziopharm is partnering with Intrexon, Merck KGaA, and MD Anderson Cancer Center on CAR-T and T-cell receptor (TCR) programs. Patient enrollment is in progress on a phase 1 study of one CAR-T therapy in treating acute myeloid leukemia (AML). The company expects two other phase 1 studies, one for a CAR-T therapy and the other for a TCR therapy, to begin in the second half of this year.

That early-stage CAR-T clinical trial should be ofparticular interest to investors. It will be Ziopharm’s first clinical study evaluating a CAR-T that can be manufactured at the point of care. If successful, it holds the promise to significantly reduce the complexity and cost associated with current approved CAR-T therapies.

The case for Bluebird

Like Ziopharm, Bluebird is developing CAR-T programs, but its lead candidates are gene therapies. The biotech’s most advanced product is LentiGlobin.The product works by inserting a functional human beta-globin gene into a patient’s own hematopoietic stem cells (undifferentiated cells that develop into various types of blood cells) outside the body. These modified stem cells are then transplanted into the patient’s bloodstream through infusion.

Bluebird plans to submit LentiGlobin for approval in Europe in the second half of 2018 for treating patients with transfusion-dependent beta-thalassemia, a rare genetic blood disorder. The company is also evaluating LentiGlobin in a phase 1 study targeting treatment of severe sickle cell disease.

Lenti-D is another gene therapy in Bluebird’s pipeline. Similar to LentiGlobin, Lenti-D involves insertion of a gene into a patient’s stem cells and the transplanting of those stem cells back into the patient’s bloodstream. Lenti-D, though, inserts afunctioning copy of the ABCD1 gene and targets treatment of cerebral adrenoleukodystrophy (CALD), a rare genetic metabolic disorder. Bluebird is evaluating Lenti-D in a phase 1/2 study and plans to present results from the study later this year.

Celgene (NASDAQ:CELG) is co-developing Bluebird’s lead CAR-T therapy, bb2121. The CAR-T immunotherapya customized lentiviral vector to modify T cells so the T cells can recognize targeted proteins on the surface of cancer cells and attack them. Celgene plans to advance bb2121 to a phase 3 clinical study as a third-line treatment for multiple myeloma.

Better buy

Both of these biotechs have promising pipelines. But I think Bluebird is the better buy right now for three key reasons.

First, Bluebird is closer to potentially having a product on the market than Ziopharm is. If all goes well, Bluebird could launch LentiGlobin next year. It’s uncertain when Ziopharm’s pivotal study forAd-RTS-hIL-12 will begin.

Second, I really like that Celgene has partnered with Bluebird. In March, the big biotech exercised its option to co-market bb2121 in the U.S. and exclusively market the CAR-T therapy outside of the U.S. That’s a great stamp of approval from a major player in the industry.

Third, Bluebird is in better shape financially. In its first-quarter results, the biotech reported a cash stockpile of $1.57 billion. By comparison, Ziopharm had $51.1 million in cash and cash equivalents on hand at the end of the first quarter.

The biggest knock against Bluebird is that its market cap of nearly $9 billion already reflects high hopes for its pipeline. There are risks that the biotech’s products could stumble in clinical trials or the regulatory approval process. Still, I think Bluebird’s chances look pretty good. It’s not the kind of stock you’d want to bet the farm on, because of the inherent risks with a clinical-stage biotech, but buying a small stake could pay off in a big way.

3 Growth Stocks at Deep-Value Prices

Sometimes, earnings grow faster than stock prices. And other times,growth stocks go on sale even though revenue is still climbing. In both cases, P/E ratios can fall to levels that make growth stocks look more like value stocks. When that happens, buying shares can lead to market-beating returns, so we asked these three Motley Fool investors if there are any growth stocks on their radar that are value-priced. They responded by recommendingCelgene Corp. (NASDAQ:CELG), Goodyear Tire & Rubber (NASDAQ:GT), and Apple Inc. (NASDAQ:AAPL). Are these growth-stock bargains worth adding to your portfoio?

A top growth stock that’s in the bargain bin

Todd Campbell (Celgene): Growth at bargain-basement prices is a bit of an oxymoron because value stocks usually aren’t double-digit growers. That’s not the case for Celgene, though.

A light bulb illuminated above a person's head in front of a blackboard covered by diagrams.

Image source: Getty Images.

Even though Celgene reported 20% year-over-year sales growth last quarter, its shares are trading at a forward P/E ratio of only 8.1. That’s a cut-rate valuation for a company that expects to deliver sales of at least $19 billion in 2020, up from $13 billion in 2017.

The low valuation is a result of a big setback Celgene suffered on a lead drug candidate in its pipeline, ozanimod. Celgene had filed for FDA approval of ozanimod for multiple sclerosis, a mega-blockbuster indication, but the FDA rejected the application, and that pushes out the timeline for a potential green light.

Celgene says it will refile for approval early in 2019, and if so, then ozanimod could begin chipping away at sales in the indication in 2020. Until then, there’s plenty going on at the company that could spark a rally in its share price again.

For instance, the company recently acquired Juno Therapeutics to get its hands on a pipeline of chimeric antigen receptor T-cell gene therapies (CAR-Ts). CAR-Ts represent one of the biggest recent advances in treating blood cancer, and depending on trial results, the first CAR-T from this collaboration could be filed for approval next year. Similarly, Celgene is partnering with bluebird bio (NASDAQ:BLUE) on bb2121, a CAR-T for multiple myeloma. So far, bb2121 is delivering 90%-plus response rates in heavily pre-treated patients, and if that success continues, it could end up on regulators’ desk for approval next year, too.

In 2018, Celgene thinks sales will be $14.8 billion, and that adjusted EPS will be $8.45. In 2017, sales and EPS were $13 billion and $7.44, respectively, so the guidance reflects a company that’s far from struggling. Given the sell-off and the potential for sales to climb significantly through 2020, buying Celgene’s shares could be smart.

Driverless cars need tires, too

Daniel Miller (Goodyear Tire & Rubber):You’ve likely heard new-vehicle sales in the U.S. are currently plateauing, which makes it difficult to sell a near-term growth story for automakers. Nonetheless, the auto industry has trends that could provide strong growth for Goodyear despite the company’sbeing sold off with the rest of the industry — it currently trades at a paltry forward P/E of 6.6, per Morningstar estimates.

Total sales are plateauing, but the sales mix is wildly shifting in favor of larger vehicles such as SUVs, crossovers, and pickup trucks. That means more larger tires on the road, and that means better margins for Goodyear. In 2009, light trucks were 45% of the U.S. new vehicle market; that exploded in the years since to 68% during the first quarter of 2018. Further, LMC Automotive predicts light trucks will generate roughly 73% of the market as soon as 2022.

A sales mix in the Americas with such a large percentage of light trucks is one growth catalyst for Goodyear, but there’s a long-term catalyst as well: driverless vehicles. Consider that by 2030, 25% of global miles traveled will be shared, according to The Boston Consulting Group, and the autonomous market will be a $7 trillion business by 2050, according to an Intel report. As the market shifts to fleet ownership, rather than individual consumers, Goodyear could leverage its physical-store tire services to sign partnerships with fleet owners, which could become a lucrative business.

Granted, the driverless-car future is an uncertain one, but one thing is certain: Tires, and other products associated with driverless cars, will become much more complex. That means growth — long-term growth — for Goodyear if it can leverage its distribution network, innovative tires, and service bays to carve out its place in the market.

Hidden in plain sight

Leo Sun (Apple): Some investors claim that Apple’s high-growth days are over. Yet the tech giant posted accelerating double-digit sales growth over the past three quarters, and analysts expect its revenue to rise 14% this year. Apple’s earnings are also expected to climb 24% this year.

Those are remarkable growth figures for a stock that trades at less than 16 times this year’s earnings. Moreover, Apple pays a forward dividend yield of 1.4%, and it has hiked that payout annually for five straight years. It also recently announced a new $100 billion buyback — which is enough to repurchase over 10% of its outstanding shares at current prices.

Apple still depends heavily on the iPhone, which generated 62% of its sales last quarter. But its services revenue — from Apple Pay, Apple Music, iTunes, its App Store, and other services — also jumped 31% annually during the quarter and accounted for 15% of its top line. Apple also stated that its paid subscriber base grew by 100 millionin the last year to 270 million.

Millennials sitting on a floor using their smartphones and tablets.

Image source: Getty Images.

That massive user base gives Apple the foundation to launch a wide variety of new services for adjacent markets — like streaming video, online news, and healthcare — to lock in users and reduce its dependence on hardware sales. That’s an advantage none of its smartphone rivals can match.

As I’ve said before, investors should think of Apple as a consumer goods company instead of a tech one. By comparing Apple’s valuations to other consumer goods companies, it’s easy to see how undervalued this stellar growth stock is.

bluebird bio Looks for Data Ahead

bluebird bio (NASDAQ:BLUE) reportedfirst-quarter earnings last week, but like the biotech typically does, management didn’t hold a conference call, which makes the earnings release more of a rehash of the quarter than an actual update.

Bluebird results: The only number that really matters

Metric

Q1 2018

Q4 2017

Quarter-Over-Quarter Change

Cash, cash equivalents and marketable securities

$1.57 billion

$1.61 billion

($48 million)

Data source: Bluebird.

What happened with Bluebird this quarter?
Without any drugs on the market, revenue and earnings aren’t particularly important for Bluebird. For the record, the company lost $115 million in the first quarter on a GAAP basis. The cash situation is arguably more important. While the change in its nest egg looks like Bluebird is being extremely frugal, the biotech actually receivedan additional $48.6 million in the first quarter from its secondary offering, negating some of the cash burn. The original Northstar (HGB-204) phase 1/2 trial completed two years of follow-up, allowing Bluebird to submit its marketing application for LentiGlobin in Europe later this year. Given the solid data for bb2121, its anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T cell (CAR T) therapy, Bluebird elected to co-develop the treatment with its partner Celgene (NASDAQ:CELG).
Doctor comforting a patient

Image source: Getty Images.

What management had to say

Nick Leschly, who goes by the title of chief Bluebird, said, “Our plans remain on track for our first regulatory filing inEuropefor [transfusion dependent beta-thalassemia], we are rapidly advancing development of bb2121 for patients, and we are focused on future innovation platforms.”

Looking forward

Investors should get some data for LentiGlobin in transfusion-dependent beta-thalassemia (TDT) patients at the European Hematology Association meeting, and for bb2121at the American Society of Clinical Oncology meeting — both of which occur next month. But as is typical for Bluebird, the big medical meeting for data will be for the American Society of Hematology (ASH), which isn’t until December. At ASH, investors can expect data for LentiGlobin in TDT and sickle cell disease as well as data for its follow-on CAR-T therapy bb21217.

This year, management also plans to lay out its plan to get LentiGlobin approved for sickle cell disease.